AU7384094A - Use of phenethanolamine derivatives in the treatment of gastrointestinal disorders - Google Patents

Use of phenethanolamine derivatives in the treatment of gastrointestinal disorders

Info

Publication number
AU7384094A
AU7384094A AU73840/94A AU7384094A AU7384094A AU 7384094 A AU7384094 A AU 7384094A AU 73840/94 A AU73840/94 A AU 73840/94A AU 7384094 A AU7384094 A AU 7384094A AU 7384094 A AU7384094 A AU 7384094A
Authority
AU
Australia
Prior art keywords
treatment
gastrointestinal disorders
phenethanolamine derivatives
phenethanolamine
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU73840/94A
Inventor
Michael Walter Foxton
Richard Howard Green
Charles David Hartley
Richard Storer
Stuart Travers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU7384094A publication Critical patent/AU7384094A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU73840/94A 1993-07-01 1994-06-29 Use of phenethanolamine derivatives in the treatment of gastrointestinal disorders Abandoned AU7384094A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9313574 1993-07-01
GB939313574A GB9313574D0 (en) 1993-07-01 1993-07-01 Medicaments
PCT/EP1994/002106 WO1995001170A2 (en) 1993-07-01 1994-06-29 Use of phenethanolamine derivatives in the treatment of gastrointestinal disorders

Publications (1)

Publication Number Publication Date
AU7384094A true AU7384094A (en) 1995-01-24

Family

ID=10738090

Family Applications (1)

Application Number Title Priority Date Filing Date
AU73840/94A Abandoned AU7384094A (en) 1993-07-01 1994-06-29 Use of phenethanolamine derivatives in the treatment of gastrointestinal disorders

Country Status (5)

Country Link
EP (1) EP0706386A1 (en)
JP (1) JPH08512038A (en)
AU (1) AU7384094A (en)
GB (1) GB9313574D0 (en)
WO (1) WO1995001170A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO179246C (en) * 1991-11-20 1996-09-04 Sankyo Co Aromatic amino-alcohol derivatives and intermediates for their preparation
ZA967892B (en) * 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
ES2171839T3 (en) 1996-09-05 2002-09-16 Lilly Co Eli CARBAZOL ANALOGS AS BETA3 SELECTIVE ADRENERGIC AGONISTS.
US5808080A (en) * 1996-09-05 1998-09-15 Eli Lilly And Company Selective β3 adrenergic agonists
GB9706707D0 (en) * 1997-04-02 1997-05-21 Glaxo Group Ltd Chemical compounds
CO5011072A1 (en) 1997-12-05 2001-02-28 Lilly Co Eli ETANOLAMINAS PIRAZINIL SUBSTITUTED AS AGFONISTS OF THE RECEPTORS
GB0102407D0 (en) 2001-01-31 2001-03-14 Glaxo Group Ltd Process
US7709677B2 (en) 2001-01-31 2010-05-04 Glaxosmithkline Llc Process of preparing arylethanoldiamines
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
JP2004526720A (en) 2001-03-08 2004-09-02 グラクソ　グループ　リミテッド β-adrenergic receptor agonist
ES2296923T3 (en) 2001-03-22 2008-05-01 Glaxo Group Limited FORMANILID DERIVATIVES AS AGONISTS OF THE BETA2 ADRENORRECEPTOR.
USRE44874E1 (en) 2001-09-14 2014-04-29 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9016655D0 (en) * 1990-07-30 1990-09-12 Ici Plc Therapeutic agents
GB9111426D0 (en) * 1991-05-28 1991-07-17 Ici Plc Chemical compounds
NO179246C (en) * 1991-11-20 1996-09-04 Sankyo Co Aromatic amino-alcohol derivatives and intermediates for their preparation
ATE215365T1 (en) * 1992-01-22 2002-04-15 Glaxo Group Ltd MEDICAL USE OF ATYPICAL BETA-ADRENOCEPTOR AGONISTS

Also Published As

Publication number Publication date
EP0706386A1 (en) 1996-04-17
WO1995001170A3 (en) 2002-02-14
JPH08512038A (en) 1996-12-17
GB9313574D0 (en) 1993-08-18
WO1995001170A2 (en) 1995-01-12

Similar Documents

Publication Publication Date Title
AU6974996A (en) Compositions for the treatment of dermatological disorders and methods for their use
AU6396598A (en) Arylsulphonamides and analogues and their use for the treatment and neurovegetative disorders
AU5687896A (en) Use of alpha 1L-agonists in the treatment of incontinence
HUP0100069A3 (en) 4(3)substituted-4(3)-aminomethyl-pyran, or -thiopyran-piperidine derivatives, their preparation and their use in the treatment of neurological disorders
AU5772196A (en) 3,4-disubstituted-phenylsulphonamides and their therapeutic use
AU3339897A (en) Sulphonamide derivatives and their use in the treatment of cns disorders
AU3725997A (en) S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
AU1173195A (en) Treatment of immunoregulatory disorders
AU5772396A (en) 3,4-disubstituted-phenylsulphonamides and their therapeutic use
AU2466695A (en) The use of famotidine and related compounds in the treatment of movement disorders
AU1542895A (en) Surface treatment
AU7384094A (en) Use of phenethanolamine derivatives in the treatment of gastrointestinal disorders
AU5590696A (en) Use of quinones in the treatment of cancer or AIDS
AU3745895A (en) Use of gaba antagonists in the treatment of emesis
AU2807492A (en) Use of misoprostol for the treatment of allergy
AU6927894A (en) 4-amidinophenylsulphonamides for the treatment of thrombo-embolitic conditions
AU1870292A (en) Use of neutral endopeptidase inhibitors in the treatment of nephrotoxicity
AU5371694A (en) Use of the tarchonanthus camphoratus
AU6581294A (en) Ethanolamine derivatives useful for the treatment of gastrointestinal disorders
AU1090995A (en) Water treatment device
AU6491890A (en) Use of arylalkylamides in the treatment of neurodegenerative diseases
AU2705495A (en) Use of rooperol and hypoxoside and their derivatives in the treatment of inflammatory
AU1485197A (en) Diamines in the treatment of arrhythmia
GB2275191B (en) Use of antifungal compounds in the treatment of skin disorders
AU7827794A (en) Human timp-3